BACKGROUND: A systematic review was undertaken to evaluate the evidence for the use of
trastuzumab as (neo) adjuvant therapy for women with HER-2/neu-positive breast cancer …

1004 Background: Neratinib (HKI-272) is an orally administered irreversible pan-ErbB
receptor tyrosine kinase inhibitor. In an ongoing phase II study, the preliminary objective …

Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast
cancer patients. However, a significant proportion of HER2-positive patients are either …

In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial
with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …

Neratinib (Nerlynx™) is an oral, irreversible inhibitor of the human epidermal growth factor
receptors HER1 (EGFR), HER2 and HER4. The drug originally arose from research by …

Background The monoclonal antibody trastuzumab has survival benefit when given with
chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 …

HER2 gene amplification and receptor overexpression is identified in 20% to 25% of human
breast cancers. Use of targeted therapy for HER2-amplified breast cancer has led to …

Purpose Neratinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor. The
efficacy and safety of neratinib were evaluated in two cohorts of patients with advanced …

Background Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival
benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer …

Background Neoadjuvant chemotherapy with trastuzumab for patients with HER2-positive
breast cancer can produce a pathological complete response in the breast in 30–65% of …